Optimization of Renin-Angiotensin System Inhibitors and Mineralocorticoid Receptor Antagonists in Patients with CKD and Heart Failure at High Risk for Hyperkalemia: Data from the CARE-HK in HF Registry
Rattachement africain : us, de, gb, au, pt, br, it, ch. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background: Patients with chronic kidney disease (CKD) are at high risk for developing cardiovascular (CV) disease which accounts for a large number of deaths in this population. Key prevention therapies include renin–angiotensin system inhibitors (RASis) and mineralocorticoid receptor antagonists (MRAs), but their use is limited by concerns about hyperkalemia (HK). Patients with heart failure (HF) and advanced CKD at high risk of HK have poorer outcomes yet are often excluded from clinical trials. Here, we characterize the clinical profile of patients with HF and CKD at high risk of HK. Methods: CARE-HK in HF is a prospective multinational registry of outpatients with HF, treated with RASis and eligible for MRAs. Risk of HK was defined as baseline serum potassium (sK+) of >5.0 mmol/L or estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2. Data were analyzed for HK events and achievement of RASi/MRA optimization (≥50% target doses). Patients were followed for a minimum of 6 months. Results: Of 2,558 (1,726 in Europe, 832 in the USA) eligible participants, the median age was 73 (interquartile range [IQR] 65–80) years, 31% were women, and 48% had type 2 diabetes. Median baseline eGFR for the entire cohort was 44 (IQR 33–60) mL/min/1.73 m2, with 1,638 (64%) having a record of CKD, 70% of whom had eGFR <45 mL/min/1.73 m2. Baseline sK+ was 4.8 (IQR 4.3–5.2) mmol/L in patients with CKD stages 3–5. In the 24 months prior to enrollment (or from RASi/MRA initiation), up to two-thirds of patients in the registry experienced at least one HK episode. Among patients with CKD, 52% experienced at least one episode of HK compared with 66% of those without CKD. RASi/MRA optimization on or after enrollment remained ≤40%. Conclusion: Patients with CKD are suboptimally treated with RASi/MRA even when sK+ is in the normal range. With appropriate monitoring and interventions, guideline-directed medical therapy could be optimized. Funding: Commercial Support - CSL Vifor
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Optimization of Renin-Angiotensin System Inhibitors and Mineralocorticoid Receptor Antagonists in Patients with CKD and Heart Failure at High Risk for Hyperkalemia: Data from the CARE-HK in HF Registry
- Date Crossref
- 01/10/2025
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Pennsylvania pays non établi dans la noticeUniversité ou école supérieure
-
Duke University pays non établi dans la noticeUniversité ou école supérieure
-
Clinical Research Institute pays non établi dans la noticeStructure de recherche
-
Saint Luke's Health System pays non établi dans la noticeÉtablissement de santé
-
University of Missouri–Kansas City pays non établi dans la noticeUniversité ou école supérieure
-
Charité - Universitätsmedizin Berlin pays non établi dans la noticeÉtablissement de santé
-
Universitätsklinikum des Saarlandes pays non établi dans la noticeÉtablissement de santé
-
Saarland University pays non établi dans la noticeUniversité ou école supérieure
-
Michael E. DeBakey VA Medical Center pays non établi dans la noticeÉtablissement de santé
-
Baylor Scott & White Health pays non établi dans la noticeÉtablissement de santé
-
University of Glasgow pays non établi dans la noticeUniversité ou école supérieure
-
The Heart Research Institute pays non établi dans la noticeStructure de recherche
University of Pennsylvania, Duke University et Clinical Research Institute, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.